sx-682
Syntrix Pharmaceuticals
['pancreatic', 'roche,(-broche),(-rocheter)']
our maintenance #immunotherapy trial evaluating sx-682, a novel dual cxcr1-2 inhibitor, plus checkpoint inhibition was highlighted in state-of-the-art care in #pancreaticcancer session at #asco23 
Leader, GI Oncology @wilmotcancer. Researcher in #cachexia, #pancreaticcancer. Girl dad, @notredame alum, tweets opinion not medical advice